Global Specialty Generics Market Report 2022: Industry Trends, Share, Size, Growth, Opportunity and Forecasts, 2016-2021 & 2022-2027 – ResearchAndMarkets.com

Global Specialty Generics Market Report 2022: Industry Trends, Share, Size, Growth, Opportunity and Forecasts, 2016-2021 & 2022-2027 – ResearchAndMarkets.com




Global Specialty Generics Market Report 2022: Industry Trends, Share, Size, Growth, Opportunity and Forecasts, 2016-2021 & 2022-2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Specialty Generics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering.

The global specialty generics market reached a value of US$ 60.8 Billion in 2021. Looking forward, the market is set to reach US$ 115.1 Billion by 2027, exhibiting at a CAGR of 11.11% during 2022-2027.

Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Specialty generics are generic versions of specialty drugs, once they get off-patent. These drugs are used to treat chronic or complex health conditions including cancer, autoimmune diseases, epilepsy, HIV, Hepatitis, multiple sclerosis, rheumatoid arthritis, etc. Specialty generics are cost-effective as compared to their branded versions as they don’t require costly development and marketing costs.

Compared to traditional generics, the specialty generics market is more concentrated with fewer players due to their complex manufacturing requirements, higher capital costs and relatively lower volumes as a result of smaller patient population.

This results in lower price reduction compared to the branded drug and consequently higher margins compared to traditional generics. Specialty generics require special handling, administration, monitoring and generally need prior authorization to order them.

The global specialty generics market is currently being driven by several factors such as rising ageing population, patent expiration of a number of branded specialty drugs, increasing prevalence of various life-threatening diseases such as cancer, multiple sclerosis, HIV, etc., cost containment measures from healthcare providers, growth from emerging markets, etc.

Key Questions Answered in This Report

  • What is the size of the global specialty generics market?
  • What are the key factors driving the global specialty generics market?
  • What has been the impact of COVID-19 on the global specialty generics market?
  • What is the breakup of the global specialty generics market based on the route of administration?
  • What is the breakup of the global specialty generics market based on the indication?
  • What is the breakup of the global specialty generics market based on the distribution channel?
  • What are the key regions in the global specialty generics market?
  • Who are the key players/companies in the global specialty generics market?

Competitive Landscape:

The global specialty generics market consists of numerous manufacturers. Some of the leading players operating in the market are:

  • Teva Pharmaceuticals Industries
  • Akorn Inc.
  • Mylan N.V.
  • Mallinckrodt
  • Sandoz International GmbH
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals
  • Apotex Corp.
  • Endo International plc.

Key Market Segmentation:

Breakup by Route of Administration:

  • Injectables
  • Oral
  • Others

Breakup by Indication:

  • Oncology
  • Autoimmune Diseases
  • Infectious Diseases
  • Others

Breakup by Distribution channel:

  • Retail Pharmacies
  • Specialty Pharmacies
  • Hospital Pharmacies

Breakup by Region:

  • North America
  • United States
  • Canada
  • Europe
  • Italy
  • Germany
  • Spain
  • United Kingdom
  • France
  • Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Latin America
  • Brazil
  • Mexico
  • Middle East and Africa

For more information about this report visit https://www.researchandmarkets.com/r/o1op9n

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900